FDA approves combination therapy for kidney cancer
SOUTH SAN FRANCISCO, Calif. The Food and Drug Administration has approved a combination therapy as a treatment for kidney cancer.
Genentech announced Monday that the FDA had approved the drug Avastin (bevacizumab) and interferon-alfa as a treatment for metastatic renal cell carcinoma, the most common form of kidney cancer. Kidney cancer is the eighth most commonly diagnosed cancer in the United States and is expected to result in the deaths of about 13,000 Americans this year, according to the American Cancer Society.
“During the last five years, Avastin has been approved by the FDA to treat five different types of cancer,” Genentech chief medical officer and VP global development Hal Barron said in a statement. “We aim to help more people facing difficult-to-treat cancers and will continue studying Avastin in more than 30 other tumor types.”
Craig C. Phillips elected VP, general manager of the oncology business unit at Cephalon
FRAZER, Pa. Cephalon announced Craig C. Phillips was elected VP and general manager of the oncology business unit.
Phillips will be responsible for managing all aspects of the U.S. oncology business including sales, marketing and medical affairs.
“Since joining Cephalon two years ago, Craig has clearly demonstrated an ability to exceed expectations and bring value to our organization through his leadership,” said Robert Roche, EVP of worldwide pharmaceutical operations. “I am confident that Craig’s leadership and vision will support the dynamic growth of the Cephalon oncology business and allow us to continue to bring medicines that matter to the healthcare professionals and patients battling cancer.”
Spartan fights economy with jump in net sales
GRAND RAPIDS, Mich. Supermarket operator Spartan Stores had a $9.3 million jump in consolidated net sales during first quarter of its fiscal year 2010, the company announced in an earnings release this week.
That and a 9.4% increase in EBITDA stemmed mostly from Spartan’s acquisition of VG’s Food and Pharmacy stores, the company said. First-quarter operating earnings increased moderately, to $15.1 million compared with first quarter fiscal year 2009.
“We are pleased to report steady operating profits despite the prolonged economic challenges and the incremental costs associated with this year’s business and operational initiatives,” Spartan president and CEO Dennis Eidson said in a statement. “As anticipated, comparable store sales at our retail supermarkets declined during the quarter due to economic uncertainty, which is causing changes in consumer purchase behavior, such as a shift to lower-priced private label products, and price deflation in certain high-volume product categories.”